2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

3230 Cyclin D1 dosage is associated with a hierarchical transcriptional state linking proliferation, genome maintenance and oxidative metabolism in mantle cell lymphoma

Mar Fernández Mañas, N/A, Neus Roca Ayats, PhD2, Robert Albero, PhD3, Sofia Karcher4, Ferran Nadeu, PhD5, Cristina Lopez, PhD6, Silvia Bea, PhD7, Guillem Clot, PhD8, Laura Valls Roca9, Glòria Garrabou, PhD10, Magda Pinyol, PhD11, Anna Enjuanes, PhD12, Helena Suarez Cisneros, PhD13, Elias Campo, MD, PhD14, Pedro Jares Gerboles, PhD15
1 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
2 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, Universitat de Vic (UVic), Vic, Catalunya, Spain
3 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
4 Hospital Clínic Barcelona, Barcelona, Catalunya, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
5 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
6 Hospital Clínic Barcelona, Barcelona, Catalunya, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
7 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
8 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
9 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain, Hospital Clínic Barcelona, Barcelona, Catalunya, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
10 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain, Hospital Clínic Barcelona, Barcelona, Catalunya, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
11 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
12 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
13 Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
14 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Hospital Clínic Barcelona, Barcelona, Catalunya, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
15 Hospital Clínic Barcelona, Barcelona, Catalunya, Spain, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, University of Barcelona (UB), Barcelona, Catalunya, Spain
Cyclin D1 overexpression is the defining molecular hallmark of mantle cell lymphoma (MCL). While Cyclin D1 is classically viewed as a regulator of cell-cycle progression, accumulating evidence suggests broader transcriptional functions beyond cell-cycle control. Whether increased Cyclin D1 activity impacts genome integrity and is associated with adaptive transcriptional programs involving DNA repair and cellular metabolism remains poorly understood.

To address this question, we first used inducible Cyclin D1 overexpression models in JVM13 cells expressing either wild-type Cyclin D1 (D1WT) or the stable nuclear mutant D1T286A. Functional studies assessed proliferation (EdU incorporation), replication stress (DNA molecular combing), and DNA damage response and checkpoint activation (flow cytometry and immunoblotting). We then integrated these findings with transcriptomic analyses from a discovery cohort of 107 primary MCL samples and five independent validation cohorts encompassing different sample sources and profiling platforms. Additional validation was performed using single-cell RNA-seq data from 18 MCL patients comprising approximately 63,000 cells, as well as pan-cancer solid tumor datasets from cBioPortal. Gene set enrichment analysis (GSEA), gene set variation analysis (GSVA), pathway correlation analyses and structural equation modeling (SEM) were used to define relationships among Cyclin D1-associated transcriptional programs.

In our in vitro model, Cyclin D1 expression increased S-phase entry and proliferation, accompanied by replication stress characterized by replication fork asymmetry, ATR-CHK1 activation and DNA damage. These effects were more pronounced in D1T286A cells than in D1WT cells, indicating a dosage-dependent effect. Cyclin D1-overexpressing cells maintained growth under low-glucose conditions, whereas control cells exhibited a marked reduction in growth. Despite this metabolic advantage, no detectable increase in basal oxygen consumption was observed, suggesting metabolic adaptation independent of baseline OXPHOS activity. Transcriptomic profiling of these models revealed induction of cell-cycle, DNA replication and DNA damage response programs, whereas oxidative phosphorylation signatures were not directly induced.

In the 107-case discovery cohort, high CCND1 expression was consistently associated with enrichment of E2F, DNA repair and oxidative metabolism programs, together with strong associations with chromosomal instability (CIN) and replication stress transcriptomic signatures. These findings were reproduced across independent MCL cohorts. GSVA and network analyses identified a transcriptional architecture in which Cyclin D1-associated programs clustered with proliferation, replication stress and CIN signatures, defining a proliferative-genomic instability module. DNA repair pathways formed a second layer closely associated with oxidative phosphorylation and metabolic programs. SEM further supported a hierarchical organization linking Cyclin D1-associated proliferative programs, DNA repair pathways and oxidative metabolic signatures.

At single-cell resolution, E2F-high/DNA repair-high/OXPHOS-high cells were significantly more frequent in Cyclin D1-high tumors (p=0.043). This triple-positive cellular state was enriched 23.8-fold above random expectation, providing orthogonal validation of the hierarchical transcriptional architecture inferred from bulk transcriptomic analyses.

Across 11 TCGA tumor types with recurrent CCND1 amplification, 7 displayed coordinated enrichment of E2F, DNA repair and oxidative metabolism signatures in CCND1-amplified tumors. A similar transcriptional architecture was independently observed in 14 of 21 tumor types when comparing tumors with high versus low Fraction Genome Altered (FGA). Together, these observations suggest that the identified network represents a recurrent transcriptional adaptation to proliferative and genomic stress across diverse human cancers.

These findings support the existence of a hierarchical transcriptional state in which Cyclin D1-associated proliferative stress is linked to coordinated activation of DNA repair and oxidative metabolism programs, providing a framework for understanding adaptation to genomic instability in MCL.
Mar Fernández Mañas, N/A: No relevant conflicts of interest to declare.